About Us
Our Vision
Bonus BioGroup strives to become a global leader in Next-Generation Therapies in cell therapy and tissue engineering to improve human health
Our mission
Our mission is to help millions of people to live a better and longer life by merging innovative biological sciences and biomedical and biotechnology engineering.
Our mission
Our mission is to help millions of people to live a better and longer life by merging innovative biological sciences and biomedical and biotechnology engineering.
2008
Bonus Biogroup founding year
2013
Establishment of Haifa facility
2014
First-in-human BonoFill™ clinical trial
2016
Successful first-in-human demonstration
2017
Launch of phase I/II BonoFill™ clinical trial
2019
Granting primary patents
2020
Launch of Phase I/II MesenCure clinical trial
2021
Phase II clinical trial for treating severe COVID patients with MesenCure.
2022
MesenCure global phase III trial and BonoFill™ phase II/III clinical trial
Our Vision
Bonus BioGroup strives to become a global leader in Next-Generation Therapies in cell therapy and tissue engineering to improve human health
Our mission
Our mission is to help millions of people to live a better and longer life by merging innovative biological sciences and biomedical and biotechnology engineering.
2022
Planned launch of MesenCure global phase III trial and BonoFill™ phase II/III clinical trial in the US
2022
2021
Completed a successful multi-center phase II clinical trial for treating severe COVID patients with MesenCure.
2020
Launch of Phase I/II clinical trial testing MesenCure, an enhanced cell therapy, in severe COVID patients.
2020
2019
Granting Bonus BioGroup’s primary patents for the generation and usage of 3D cell-based bone implants.
2017
Launch of phase I/II clinical trial evaluating the safety and efficacy of BonoFill™ in orthopedic indications.
2017
2016
Successful first-in-human demonstration of the safety and efficacy of BonoFill™ and launch of phase I/II clinical trial testing 2nd generation BonoFill™ for maxillofacial bone regeneration.
2014
Launch of the first-in-human clinical trial with BonoFill™, an injectable bone graft for maxillofacial bone regeneration
2014
2013
Establishment of the world’s first live human bone graft manufacturing facility in Haifa, Israel
2008
Bonus* was founded by experts in tissue engineering and cell therapy led by Dr. Shai Meretzki, who pioneered the industrial development of mesenchymal cell therapies. <read more> *Bonus Therapeutics Ltd., a wholly-owned subsidiary of Bonus BioGroup Ltd.
2008
info@bonus-bio.com
+972 (0)73 206 7104
Matam Advanced Technology
